In a filing, Verona Pharma Plc ADR revealed its Director Cunningham Kenneth unloaded Company’s shares for reported $0.14 million on Aug 01 ’25. In the deal valued at $13.14 per share,10,808 shares were sold. As a result of this transaction, Cunningham Kenneth now holds 79,776 shares worth roughly $8.4 million.
Then, Deschamps Lisa sold 9,464 shares, generating $124,392 in total proceeds. Upon selling the shares at $13.14, the Director now owns 84,856 shares.
Before that, Fisher Andrew sold 9,584 shares. Verona Pharma Plc ADR shares valued at $125,969 were divested by the General Counsel at a price of $13.14 per share. As a result of the transaction, Fisher Andrew now holds 417,903 shares, worth roughly $44.0 million.
H.C. Wainwright downgraded its Verona Pharma Plc ADR [VRNA] rating to a Neutral from a a Buy in a research note published recently. A number of analysts have revised their coverage, including Wolfe Research’s analysts, who began to cover the stock in early July with a ‘”an Outperform”‘ rating. TD Cowen began covering VRNA with “Buy” recommendation on April 28, 2025. Cantor Fitzgerald started covering the stock on April 21, 2025. It rated VRNA as “an Overweight”.
Price Performance Review of VRNA
On Friday, Verona Pharma Plc ADR [NASDAQ:VRNA] saw its stock fall -0.11% to $105.28. Over the last five days, the stock has gained 0.10%. Verona Pharma Plc ADR shares have risen nearly 402.29% since the year began. Nevertheless, the stocks have risen 126.70% over the past one year.
How much short interest is there in Verona Pharma Plc ADR?
A steep rise in short interest was recorded in Verona Pharma Plc ADR stocks on 2025-07-15, dropping by -4.36 million shares to a total of 4.06 million shares. Yahoo Finance data shows the prior-month short interest on 2025-06-13 was 8.42 million shares. There was a decline of -107.31%, which implies that there is a negative sentiment for the stock.
The most recent change occurred on January 10, 2025 when ROTH MKM began covering the stock and recommended ‘”a Buy”‘ rating along with a $68 price target.
